Galderma’s survey highlights confusion about menopause-related skin changes. Read the findings, trial caveats and practical questions for qualified care.
On October 13, 2026, Galderma announced that 56% of respondents in its commissioned survey initially attributed menopause-related skin changes to general aging. Another 29% said they initially recognized a connection to menopause. The company also released results from an injectable-treatment trial it supported.
The announcement pairs a question about understanding skin with a question about treatment. For readers trying to make sense of midlife changes, separating those questions keeps the story focused on evidence rather than on a product.
The biological starting point is straightforward: hormonal changes during perimenopause and menopause can affect skin, as Galderma’s announcement notes. The survey asks how women understood changes associated with that transition. Its central finding concerns their initial interpretation, rather than a newly identified biological pathway.
The treatment research addresses two aspects of skin: hydration and remodeling. In everyday language, those mean moisture and changes in skin structure. Measuring dermal thickness focuses on structure; asking participants about natural-looking results focuses on their experience. Those outcomes answer different questions.
Dr. Andreas Nikolis, who led the investigator-initiated trial, described a rationale of hydration-focused Restylane Skinboosters first and Sculptra afterward. The trial compared that order with the reverse sequence on the face and décolletage in menopausal women.
According to Galderma, Perspectus Global surveyed 5,090 women who had experienced or were experiencing perimenopause or menopause. Respondents were in the UK, US, Brazil and China. Data were collected from August 25 to September 1, 2026.
The 56% attribution response and the 29% menopause-link response describe what respondents recalled thinking initially. Galderma also reported several findings about skincare decisions:
Galderma also said one in two surveyed women remained unaware that hormonal changes during perimenopause and menopause can affect skin. That response concerns awareness at the time of the survey. It is separate from the 56% figure about respondents’ initial attribution of skin changes.
Separately, Galderma reported results from the eight-month trial it supported. The company reported facial dermal-thickness increases of 27.3% with Restylane Skinboosters followed by Sculptra and 15.7% with the reverse sequence. It also reported improvements in hydration in both groups.
The announcement said 98% of participants described results as natural-looking. It reported that 96% would recommend the treatments and 92% would undergo treatment again. These are participant-reported responses, distinct from the measurements of skin structure.
Fierce Pharma’s coverage highlighted the same survey awareness findings and the reported relationship between treatment sequence and facial dermal thickness.
The survey and trial were described in Galderma’s announcement using references to “Data on file.” The accessible accounts provide company-reported findings, not an independent assessment of trial methods.
For the survey, the public details omit the questionnaire and recruitment methods. They also omit the response rate and weighting approach. The sample spans four countries, but that does not make it representative of all women or other places. Respondents’ initial interpretations are not clinical diagnoses of what caused their skin changes.
The purchasing finding also records a belief about products. It does not establish that respondents bought unsuitable skincare or that their purchases failed. Likewise, the wish to feel better informed does not demonstrate that any particular education campaign will improve decisions.
For the trial, the announcement does not supply enrollment or group sizes. Randomization and blinding status are not given. Neither are detailed statistical analyses, confidence intervals or safety and adverse-event results. The satisfaction percentages also lack participant denominators.
The difference between the reported thickness increases does not establish statistical significance or prove a superior sequence. The eight-month study period does not establish longer-term outcomes. Nor did the announcement describe a comparison with non-injectable options. Trial results therefore should not be treated as a forecast of an individual’s real-world experience.
For women navigating perimenopause or menopause, the practical takeaway is to bring the hormonal-transition context into conversations about skin. The goal is not to replace one blanket explanation with another. It is to describe the concern clearly and discuss it with a qualified clinician.
That conversation can sit within the broader context of skin changes around menopause, rather than being framed only by a product label. A useful starting question is whether the hormonal transition may be relevant to the changes being discussed. Personal decisions belong with qualified care, not with a survey percentage.
For day-to-day beauty decisions, consider what is changing, what explanation needs clarification and what evidence supports an option. That approach gives a clinician something more specific to address than a general request for a younger-looking complexion. It also keeps marketing language from setting the terms of the conversation.
Routine skincare and injectable procedures also deserve separate consideration. Reading about barrier-focused routine decisions can help frame the everyday-care side of that discussion. Questions about procedures belong in a consultation that addresses their evidence and personal suitability.
For someone considering the reported injectable sequence, useful questions for a qualified clinician include:
The purpose of those questions is an informed discussion, not a preferred answer. Understanding a skin concern and deciding whether to pursue an aesthetic procedure are separate decisions. Neither needs to be settled by the language of an announcement.
The survey brings attention to a practical question: how does a woman’s first explanation for a skin change relate to the products she considers? Galderma’s reported purchasing responses make that connection worth examining. Clearer communication about menopause-related skin would be valuable even without a new treatment announcement.
For readers following the broader skin-longevity conversation, the next advance should be useful knowledge rather than a more persuasive label. Future research could connect women’s priorities with clearly defined outcomes and independent clinical assessment. That would make the conversation about looking and feeling well over time more grounded.
Will the next wave of menopause skin research help women understand their changing skin while giving clinicians stronger evidence for genuinely individualized decisions?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
